Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fredda Schafer is active.

Publication


Featured researches published by Fredda Schafer.


Infection and Immunity | 2002

Differences in components at delayed-type hypersensitivity reaction sites in mice immunized with either a protective or a nonprotective immunogen of Cryptococcus neoformans.

Kasie L. Nichols; Sean K. Bauman; Fredda Schafer; Juneann W. Murphy

ABSTRACT Cell-mediated immunity is the major protective mechanism against Cryptococcus neoformans. Delayed swelling reactions, i.e., delayed-type hypersensitivity (DTH), in response to an intradermal injection of specific antigen are used as a means of detecting a cell-mediated immune (CMI) response to the antigen. We have found previously that the presence of an anticryptococcal DTH response in mice is not always indicative of protection against a cryptococcal infection. Using one immunogen that induces a protective anticryptococcal CMI response and one that induces a nonprotective response, we have shown that mice immunized with the protective immunogen undergo a classical DTH response characterized by mononuclear cell and neutrophil infiltrates and the presence of gamma interferon and NO. In contrast, immunization with the nonprotective immunogen results in an influx of primarily neutrophils and production of tumor necrosis factor alpha (TNF-α) at the DTH reaction site. Even when the anticryptococcal DTH response was augmented by blocking the down-regulator, CTLA-4 (CD152), on T cells in the mice given the nonprotective immunogen, the main leukocyte population infiltrating the DTH reaction site is the neutrophil. Although TNF-α is increased at the DTH reaction site in mice immunized with the nonprotective immunogen, it is unlikely that TNF-α activates the neutrophils, because the density of TNF receptors on the neutrophils is reduced below control levels. Uncoupling of DTH reactivity and protection has been demonstrated in other infectious-disease models; however, the mechanisms differ from our model. These findings stress the importance of defining the cascade of events occurring in response to various immunogens and establishing the relationships between protection and DTH reactions.


PLOS ONE | 2013

Identification of Class I HLA T Cell Control Epitopes for West Nile Virus

Saghar Kaabinejadian; Paolo Piazza; Curtis McMurtrey; Stephen Vernon; Steven Cate; Wilfried Bardet; Fredda Schafer; Kenneth W. Jackson; Diana M. Campbell; Rico Buchli; Charles R. Rinaldo; William H. Hildebrand

The recent West Nile virus (WNV) outbreak in the United States underscores the importance of understanding human immune responses to this pathogen. Via the presentation of viral peptide ligands at the cell surface, class I HLA mediate the T cell recognition and killing of WNV infected cells. At this time, there are two key unknowns in regards to understanding protective T cell immunity: 1) the number of viral ligands presented by the HLA of infected cells, and 2) the distribution of T cell responses to these available HLA/viral complexes. Here, comparative mass spectroscopy was applied to determine the number of WNV peptides presented by the HLA-A*11:01 of infected cells after which T cell responses to these HLA/WNV complexes were assessed. Six viral peptides derived from capsid, NS3, NS4b, and NS5 were presented. When T cells from infected individuals were tested for reactivity to these six viral ligands, polyfunctional T cells were focused on the GTL9 WNV capsid peptide, ligands from NS3, NS4b, and NS5 were less immunogenic, and two ligands were largely inert, demonstrating that class I HLA reduce the WNV polyprotein to a handful of immune targets and that polyfunctional T cells recognize infections by zeroing in on particular HLA/WNV epitopes. Such dominant HLA/peptide epitopes are poised to drive the development of WNV vaccines that elicit protective T cells as well as providing key antigens for immunoassays that establish correlates of viral immunity.


Cancer Letters | 1977

Purification of shed human melanoma proteins by affinity chromatography

Fredda Schafer; Michael P. Lerner; J.H. Anglin; Robert E. Nordquist

Summary Naturally shed proteins from cultured human melanoma cells were separated from the growth medium by Con A affinity chromatography. Analysis of the separated components by polyacrylamide gel electrophoresis and gel chromatography indicated that there were three major groups of macromolecules. One group contained a glycolipoprotein similar to the reported human melanoma antigen.


Journal of Immunology | 2016

Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late

Saghar Kaabinejadian; Curtis McMurtrey; Sojung Kim; Rinki Jain; Wilfried Bardet; Fredda Schafer; Jason L. Davenport; Aaron D. Martin; Michael S. Diamond; Jon A. Weidanz; Ted H. Hansen; William H. Hildebrand

Class I HLA molecules mark infected cells for immune targeting by presenting pathogen-encoded peptides on the cell surface. Characterization of viral peptides unique to infected cells is important for understanding CD8+ T cell responses and for the development of T cell–based immunotherapies. Having previously reported a series of West Nile virus (WNV) epitopes that are naturally presented by HLA-A*02:01, in this study we generated TCR mimic (TCRm) mAbs to three of these peptide/HLA complexes—the immunodominant SVG9 (E protein), the subdominant SLF9 (NS4B protein), and the immunorecessive YTM9 (NS3 protein)—and used these TCRm mAbs to stain WNV-infected cell lines and primary APCs. TCRm staining of WNV-infected cells demonstrated that the immunorecessive YTM9 appeared several hours earlier and at 5- to 10-fold greater density than the more immunogenic SLF9 and SVG9 ligands, respectively. Moreover, staining following inhibition of the TAP demonstrated that all three viral ligands were presented in a TAP-dependent manner despite originating from different cellular compartments. To our knowledge, this study represents the first use of TCRm mAbs to define the kinetics and magnitude of HLA presentation for a series of epitopes encoded by one virus, and the results depict a pattern whereby individual epitopes differ considerably in abundance and availability. The observations that immunodominant ligands can be found at lower levels and at later time points after infection suggest that a reevaluation of the factors that combine to shape T cell reactivity may be warranted.


Infection and Immunity | 1998

Antigen-Induced Protective and Nonprotective Cell-Mediated Immune Components against Cryptococcus neoformans

Juneann W. Murphy; Fredda Schafer; Arturo Casadevall; Adekunle M. Adesina


Journal of Pharmaceutical Sciences | 1998

Liposomes, a Potential Immunoadjuvant and Carrier for a Cryptococcal Vaccine

Maria P. Lambros; Fredda Schafer; Rebecca Blackstock; Juneann W. Murphy


Human Immunology | 2015

Comparison of HLA-A and HLA-B ligandomes

Curtis McMurtrey; Wilfried Bardet; Sean Osborn; Kenneth W. Jackson; Fredda Schafer; William H. Hildebrand


Human Immunology | 2015

West nile virus ligands from alternative reading frame proteins are revealed by class I HLA

Saghar Kaabinejadian; Cutis McMurtrey; Wilfried Bardet; Fredda Schafer; Kenneth W. Jackson; William H. Hildebrand


Journal of Immunology | 2014

HIV-1 NEF ligands predominate in the HLA class I of infected CD4+ T cells (APP2P.108)

Jane C. Yaciuk; S. Smith; Matthew Skaley; Curtis McMurtrey; Wilfried Bardet; Fredda Schafer; Danijela Mojsilovic; Christopher Stewart; Steven Cate; Kenneth W. Jackson; Jon A. Weidanz; Alex Olvera van der Stoep; Christian Brander; John T. West; William H. Hildebrand


Journal of Immunology | 2013

Immunodominant and subdominant WNV epitopes are differentially presented (P5005)

Curtis McMurtrey; Sojung Kim; Wilfried Bardet; Fredda Schafer; Michael S. Diamond; Jon A. Weidanz; Ted H. Hansen; William H. Hildebrand

Collaboration


Dive into the Fredda Schafer's collaboration.

Top Co-Authors

Avatar

William H. Hildebrand

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Wilfried Bardet

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Curtis McMurtrey

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Rico Buchli

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Kenneth W. Jackson

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Angela R. Wahl

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Danijela Mojsilovic

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Gillian M. Air

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Jon A. Weidanz

Texas Tech University Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Saghar Kaabinejadian

University of Oklahoma Health Sciences Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge